TCGA-CR-7398-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.370
- E2F_TARGETS+0.320
- G2M_CHECKPOINT+0.290
- MITOTIC_SPINDLE+0.140
- SPERMATOGENESIS+0.100
- UV_RESPONSE_DN+0.060
- ANGIOGENESIS+0.050
- KRAS_SIGNALING_DN+0.040
- MYC_TARGETS_V1+0.040
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.010
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- TNFA_SIGNALING_VIA_NFKB-0.510
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.500
- INTERFERON_GAMMA_RESPONSE-0.480
- OXIDATIVE_PHOSPHORYLATION-0.390
- INFLAMMATORY_RESPONSE-0.370
- P53_PATHWAY-0.370
- PROTEIN_SECRETION-0.370
- CHOLESTEROL_HOMEOSTASIS-0.350
- COMPLEMENT-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_VAAHBH60 | EPN | Supratentorial EPN | 0.916 |
| 2 | BS_VVFBW0YH | medulloblastoma | — | 0.908 |
| 3 | MNG459 | — | — | 0.906 |
| 4 | BS_4E1G7E3G | ATRT | — | 0.905 |
| 5 | BS_44A3ES23 | medulloblastoma | — | 0.899 |
| 6 | BS_VPBMDMQX | medulloblastoma | — | 0.898 |
| 7 | BS_S1M423AB | Embryonal tumors | — | 0.898 |
| 8 | BS_77317DY4 | medulloblastoma | — | 0.896 |
| 9 | SAMN03290896 | — | — | 0.893 |
| 10 | C3N-03886 | — | cohortMD1 | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.060 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.050 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.040 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.010 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.010 | Inavolisib | — uncovered |